Skin + Me has secured £10m to further develop its personalisation skin care strategy as customer demand ramps up.
The D2C skintech start-up – which delivers bespoke, dermatologist designed treatments using prescription-only ingredients – closed a Series B funding round with capital investor Octopus Ventures.
The investment will boost innovations within its online prescription service and accelerate activity in new marketing channels.
Skin + Me’s business has grown 100% year-on-year since it launched in 2020.
It has prescribed millions of products to hundreds of thousands of customers.
The business is now cash generative.
Skin + Me’s business has grown 100% year-on-year
The start-up also experienced a 50% uptake in its range of supplementary cosmetic moisturisers and cleansers, which launched last year.
“We have seen consumer awareness for prescription-only ingredients such as tretinoin grow exponentially,” said Horatio Cary, CEO of Skin + Me.
“We expect the £140bn global skin care spend to shift quickly towards prescription-strength ingredients and [we are] ideally placed… to take advantage of this trend.”
Will Gibbs, Healthtech Partner at Octopus Ventures, commented: “Increased awareness in prescription ingredients and a growing trend towards personalisation has transformed the skin care market.
“Skin + Me lead the charge with its accelerated growth, reflecting a step change that has seen hyper-educated consumers shun off-the-shelf products in favour of highly efficacious solutions.”
Read more:
- Faace secures £165,000 to grow its skin care range and online presence
- Unilever Ventures injects $2 million into scalp care brand Straand
- Make-up by Mario secures $40 million minority investment to expand the brand